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GObjective(s): Recommendations for surveillance after stereotactic body radiation therapy (SBRT) for early
stage non–small cell lung cancer (NSCLC) are not well defined. Prospective studies evaluating the efficacy
of SBRT have used interval posttreatment imaging with computed tomography (CT). We set out to determine
whether positron emission tomography (PET) combined with diagnostic chest CT (PET/d-chest) can enhance
detection of potentially salvageable recurrence after SBRT.
Methods:We performed a retrospective analysis of posttreatment imaging for 35 patients consecutively treated
with SBRT for biopsy-proven early-stage NSCLC. PET/d-chest was generally performed every 3 months after
treatment. A board-certified radiologist who did not have access to the PET results retrospectively interpreted the
CT scans. CT results were reported according to response criteria used in Radiation Therapy Oncology Group
0236 and compared with PET/d-chest readings. Local and regional recurrence-free survival was compared using
the Mantle-Cox (log–rank) test.
Results:Median follow-up was 12.8 months. Twenty-four patients had stage IA, 7 stage IB, 3 stage IIA, and 1
stage IIB biopsy-proven NSCLC. Two-year overall survival was 62%. CT scans indicated no regional recur-
rences. PET/d-chest indicated 10 regional recurrences. The 1-year rate of regional recurrence-free survival as
evaluated by CTand PET/d-chest was 100% and 69.4%, respectively (P¼ .0045). Four of 10 patients with a di-
agnosis of regional recurrence underwent salvage treatment with definitive chemoradiotherapy.
Conclusions: PET/d-chest enhances the detection of regional progression of NSCLC after SBRTover currently
recommended practices. In patients who are fit for salvage treatment, where early detection of recurrence can
increase the likelihood of successful treatment, PET/d-chest appears critical for follow-up. (J Thorac Cardiovasc
Surg 2013;145:709-15)Earn CME credits at
http://cme.ctsnetjournals.org
Stereotactic body radiation therapy (SBRT) is emerging as
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The Journal of Thoracic and Cahave been systematically evaluated in phase I and II
clinical trials1-4 and shown to have excellent response
rates, with local control and survival superior to
historically compared results for conventionally
fractionated radiation therapy.5
Inasmuch as new multicenter clinical trials may expand
the indications of SBRT to high-risk patients with operable
disease, questions remain regarding the optimal surveil-
lance protocol after treatment. Neither National Compre-
hensive Cancer Network (NCCN) nor the American
Society for Therapeutic Radiology and Oncology (ASTRO)
clinical practice guidelines for SBRT of lung cancer make
specific recommendations for follow-up after SBRT.6 Phase
II trials have typically included 3-month interval posttreat-
ment imaging: alternating computed tomography (CT) and
chest radiography.7 Recent Radiation Therapy Oncology
Group (RTOG) studies of SBRT have not routinely included
the use of positron emission tomography (PET) for follow-
up owing to concerns that flurodeoxyglucose (FDG) activity
persists after treatment for up to 2 years, limiting its utility
to assess in-field recurrence.8,9 However, because many
failures occur within regional lymphatic basins (ie, hilarrdiovascular Surgery c Volume 145, Number 3 709
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ACOSOG ¼ American College of Surgeons
Oncology Group
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Sand mediastinal), it is critical that these recurrences be
detected as early as possible in patients who may be able
to tolerate additional salvage treatment. Concern exists
that basic anatomic imaging is inadequate in this
population, and a prior prospective study has shown that
PET/CT performed 3 months after conventionally
fractionated definitive radiation therapy discovered
potentially salvageable disease in asymptomatic patients
more frequently than CT alone.10
In recognition of the relative insensitivity of CT for de-
tectingmediastinal nodal recurrences because of its reliance
on morphology and size,11 and the superiority of combined
PET/CT, which uses metabolic and morphologic informa-
tion,12 we opted to monitor treated patients with diagnostic
level chest CT using intravenous contrast in combination
with 18-FDG-PET imaging (PET/d-chest) in 3-month inter-
vals. We observed that most (if not all) of the regional (ie,
hilar/mediastinal nodal) recurrences detected were done so
by the PET portion of the PET/d-chest study. We therefore
hypothesized that the addition of PET imaging to diagnostic
chest CT increased the sensitivity of regional recurrence de-
tection and enhanced early discovery of salvageable disease.
As such, we performed a retrospective review of the patients
treated at our institution to determine the relative utility of
diagnostic chest CT and PET/d-chest for surveillance of
patients treated with SBRT for early-stage NSCLC.PATIENTS AND METHODS
Patients
After obtaining institutional review board approval, including thewaiver
of individual patient consent, we conducted a retrospective review of 40710 The Journal of Thoracic and Cardiovascular Surgpatients with medically inoperable disease consecutively treated with
SBRT for biopsy-proven early stage (T1a-T3, N0 M0) NSCLC at Boston
Medical Center from February 2009 until February 2012. Follow-up imag-
ing was only available for 35 of the 40 patients. Of the 5 patients not ana-
lyzed, 3 refused to travel to our institution for follow-up and were seen by
their referring oncologists close to their homes, 1 died 4 weeks after treat-
ment of a myocardial infarction, and 1 had brain metastases develop before
the first scheduled follow-up imaging. The baseline characteristics for these
35 patients are presented in Table 1. Medical inoperability was determined
by board-certified thoracic surgeons (M.I.E., H.C.F.). It should be noted that
forced expiratory volume in 1 second and/or diffusing capacity of carbon
monoxide of less than 40% predicted was common, but certainly not suffi-
cient, to conclude medical inoperability. Included were 6 surgical refusals.
Pretreatment assessment and staging were accomplished with diagnos-
tic chest CTwith intravenous contrast, PET/CT, imaging of the central ner-
vous system with either contrast-enhanced brain magnetic resonance
imaging or head CT, and in select cases, invasive mediastinal/hilar staging
with cervical mediastinoscopy and/or endobronchial ultrasound (EBUS)
guided lymph node biopsies. After evaluation, all patients were believed
to have no regional lymph node metastases. In all patients, staging was ac-
cording to the seventh edition of the American Joint Commission on Cancer
Staging Manual. Tissue confirmation of NSCLC was obtained in all pa-
tients and gold fiducial markers were typically placed at the time of biopsy.
SBRT Delivery
All SBRT treatments were delivered at our institution on a CyberKnife
Robotic Stereotactic Radiosurgery System (Accuray, Inc, Sunnyvale,
Calif). Patients were positioned for treatment in a body-length vacuum
cushion with arms down for comfort. Treatment planning was done with
noncontrast chest CT performed in the radiology department on a GE
Lightspeed 64 Slice CT scanner (GE Medical Imaging, Waukeshka,
Wis). Images were imported into theMultiPlan CyberKnife treatment plan-
ning system (Accuray, Inc, Sunnyvale, Calif).
The gross tumor volumewas defined by the treating radiation oncologist
and thoracic surgeon as the tumor visible on lung windowed CT scan. A
margin of at least 5 mm was added to the gross tumor volume to define
the planning target volume. Relevant critical structures (eg, lungs, spinal
cord, proximal bronchial tree, esophagus) were also defined. Treatment
plans were formulated to treat at least 95% of the planning target volume
with 50 to 60 Gy in 3 to 5 fractions with the biologically equivalent dose
greater than 100 Gy10 for every treatment course. The first 24 treatment
plans were calculated with the Ray-Tracing algorithm, and the subsequent
11 were calculated with the Monte Carlo algorithm. Prescription isodose
line was between 60% and 90%. Radiation dose to critical structures
was limited to acceptable and safe levels.
All treatments were delivered with image guidance using implanted fi-
ducial markers as surrogates for tumor location, and the Synchrony Respi-
ratory Tracking System (Accuray, Inc, Sunnyvale, Calif) was used for all
cases. Patients were pretreated with 4 mg of dexamethasone on days of
treatment and SBRT treated on nonconsecutive days.
Radiographic Assessment and Follow-up
Follow-up plan on completion of SBRT included every 3-month PET/d-
chest for the first 2 years. In the event that a recurrence was detected on
PET/d-chest, pathologic confirmation was pursued unless a patient was be-
lieved too frail to tolerate any salvage or palliative treatment. Pathologic
confirmation of mediastinal and/or hilar lymph node recurrence was per-
formed with cervical mediastinoscopy, EBUS, and/or endoscopic esopha-
geal ultrasound.
All PET/CT studies were performed on a GE Discovery STE 16 (Gen-
eral Electric, Waukeshka, Wis) PET/CT scanner. First, PET/CT imaging
was done in conjunction with a low-dose CT for attenuation correction.
Patients were scanned from skull base to mid thigh and injected with an
average of 11.0 mCi 18FDG. Immediately thereafter, a dedicatedery c March 2013
TABLE 1. Baseline patient characteristics
Characteristic
Patients (n ¼ 35)
n %
Gender
Male 15 43
Female 20 57
Age
60 y 1 3
>60-70 y 15 43
>70-80 y 14 40
>80-90 y 4 11
>90 y 1 3
PS (ECOG)
2 20 57
3 15 43
Reason for inoperability
Poor pulmonary function
(FEV1 and/or DLCO<40%)
20 57
Other cardiopulmonary 8 23
Other medical* 3 9
Refusal of surgery 4 11
Tumor size
2 cm 17 49
>2-3 cm 11 31
>3-5 cm 5 14
>5 2 6
AJCC T stage
T1 24 69
T2 10 28
T3 1 3
Tumor location
Central 5 14
Peripheral 30 86
Histology
Adenocarcinoma 14 40
Squamous 15 43
NSCLC (NOS) 6 17
N0 status
cN0y 22 63
pN0z 13 37
EBUS 5 14
Mediastinoscopy 4 11
EBUS þ mediastinoscopy 4 11
PS, Performance status; ECOG, Eastern Cooperative Oncology group; FEV1, forced
expiratory volume in 1 second;DLCO, diffusing capacity of carbonmonoxide;AJCC,
American Joint Commission on Cancer; NSCLC, non–small cell lung cancer; NOS,
nitric oxide synthase; EBUS, endobronchial ultrasound. *One patient with AIDS
and CD4<200; one patient debilitated after cerebrovascular accident; one patient
with Alzheimer disease. ycN0 ¼ clinically staged hilum/mediastinum.
zpN0 ¼ pathologically staged hilum/mediastinum.
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Scontrast-enhanced diagnostic level chest CT was performed without mov-
ing the patient; this setup allowed image fusion of PET and contrast-
enhanced diagnostic chest CT. The contrast-enhanced diagnostic chest
CT used 120 mL of Optiray 320 intravenous contrast (Tyco Health Care/
Mallinckrodt, Raleigh, NC). The contrast was timed to achieve optimal en-
hancement for liver and pulmonary vasculature.
To compare the utility of CT and PET/d-chest for detection of regional
recurrence, and to eliminate potential bias introduced by having access to
both PETand d-chest images/reports, we had each diagnostic chest CT scanThe Journal of Thoracic and Caread independently by a board-certified radiologist with specialization in
chest imaging. PET images were uncoupled from the diagnostic CT im-
ages, and he/she was blinded to the PET result. CT response assessment
was performed according to the modified version of the Response Evalua-
tion Criteria in Solid Tumors (RECIST) Committee criteria used to assess
tumor burden. It was by these parameters that response within the planning
target volume was determined. Local failure was also characterized by re-
currence within the treated lobe, consistent with definitions established by
RTOG 0236 and ACOSOG Z4099 (American College of Surgeons Oncol-
ogy Group). Regional failure was considered to have occurred if lymph no-
des greater than 1 cm in short-axis diameter appeared in the expected
lymphatic hilar or mediastinal drainage path of the primary tumor. All other
recurrences were considered local or distant.
Statistics
Rates of regional recurrence-free survival (rRFS) were calculated for
the entire patient group on the basis of the results of PET/d-chest and CT
alone. Once a recurrence was suspected by a specific follow-up modality,
subsequent studies of that same modality were not considered, irrespective
of whether additional studies existed. In addition, the rate of biopsy-proven
rRFS was determined by removing patients with clinically detected yet un-
biopsied recurrences. Overall survival was calculated from first SBRT
treatment until the time of last follow-up or death; the Social Security
Death Index was searched in the event that a patient was lost to follow-up.
GraphPad Prism Statistical Software Package (GraphPad Software, La
Jolla, Calif) was used to calculate rRFS, biopsy-proven rRFS, and overall
survival usingMantle-Cox (log–rank) statistics; Kaplan-Meier curves were
constructed for each.RESULTS
The median follow-up time for the entire patient popula-
tion was 12.8 months (range, 0.3-36.9 months). At the time
of this report, 14 patients have died. The 1-year and 2-year
rates of overall survival were 77% and 62%, respectively
(Figure 1).
Twenty (57%) patients did not have any recurrence of
their cancer. For the remainder of the patients, the first
site of cancer recurrence was as follows: 10 (28.6%) in re-
gional lymph nodes (ie, hilar and/or mediastinal), 1 (2.8%)
in the central nervous system, 2 (5.7%) with pleural
dissemination, 1 (2.8%) with an adrenal metastasis, and
1 (2.8%) with recurrence in the same lobe as the primary
tumor. One of the regional recurrences occurred simulta-
neously with a new nodule in the same treated lobe more
than 24 months after initial treatment. No recurrences
were detected within the planning target volume according
to modified RECIST criteria. There was no difference in the
rates of recurrence when stratified by T descriptor.
The rRFS was evaluated by 2 means: PET/d-chest and di-
agnostic CT alone. Regional recurrence was detected in 10
(28.6%) patients when they were evaluated by PET/d-chest.
These regional recurrences occurred between 2.9 and 29
months after treatment (median, 4.45 months). Diagnostic
CT alone detected no regional recurrences after treatment.
The 2-year rates of rRFS as evaluated by CT and PET/d-
chest are 100% and 52.1%, respectively. Of note, 2 of the
patients with regional recurrence detected by PET/d-chest
did have pathologic staging before treatment; the remainingrdiovascular Surgery c Volume 145, Number 3 711
FIGURE 1. Kaplan-Meier curve for overall survival (OS) for 35 patients
treated with stereotactic body radiation therapy for medically inoperable
early-stage non–small cell lung cancer. Median survival time for this group
of patients is 28.6 months. Data summary table indicates number of
patients at risk at 0, 6, 12, 18, and 24 months with corresponding percent
overall survival for each time point.
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S8 were staged clinically as N0. Figure 2, A, shows the com-
parison of Kaplan-Meier curves for rRFS based on follow-
up imaging modality.
Six of the 10 patients with regional recurrences as deter-
mined by PET/d-chest did have biopsy confirmation; there
was only 1 patient for whom an attempt at biopsy was
unsuccessful; however, this patient did go on to receive sal-
vage treatment (mediastinal chemoradiation) because of
a high degree of suspicion based on imaging characteristics.
The biopsy-proven regional recurrences occurred between
2.9 and 16.5 months after treatment (median, 4.95 months).FIGURE 2. Kaplan-Meier curves comparing (A) rRFS for 35 patients treated
biopsy-proven rRFS for the same 35 patients (B). A, Open circles (B) indicate
between these 2 graphs is statistically significant (P ¼ .0045). B, Open circles
gional recurrence that were picked up by PET/d-chest that were subsequently pa
remains statistically significant (P¼ .03). Data summary table in A and B indica
ing percent rRFS or biopsy-proven rRFS for each time point, respectively. rRFS
apy;NSCLC, non–small cell lung cancer;CT, computed tomography;PET/d-che
tomography; PET, positron emission tomography.
712 The Journal of Thoracic and Cardiovascular SurgOnly 1 patient with biopsy-proven regional recurrence was
staged pathologically. The 1- and 2-year rates of biopsy-
proven rRFS as evaluated by PET/d-chest are 82.6% and
62%, respectively. Figure 2, B, shows the comparison of
Kaplan-Meier curves for both biopsy-proven rRFS and clin-
ical rRFS as determined by CT.DISCUSSION
Stereotactic body radiotherapy for patients with medi-
cally inoperable, early stage, N0 NSCLC has been estab-
lished as a new standard of care. Before the wide
acceptance of SBRT for this patient population, the only
available options were conventionally fractionated radia-
tion therapy, thermal ablation, or supportive care alone.
Median survival time for patients with untreated stage I
NSCLC ranges between 8 and 14 months with approxi-
mately 75% of patients dying of NSCLC.13 Conventionally
fractionated radiotherapy provides only marginal benefit,
with median survival times between 1.5 and 1.7 years.5 In
contrast, SBRT yields a significant improvement in out-
comes, with median survival times up to 48months reported
in multicenter trials. In our series of 35 patients treated with
SBRT, the 2-year overall survival was 62% with a median
survival time of 28.6 months. This is consistent with the re-
sults of the prospective multicenter RTOG 0236 trial, con-
sidered the modern benchmark for lung SBRT.7
In the early phase of our SBRT program, we noted
a higher than expected incidence of recurrence within re-
gional lymph nodes. On the basis of published reports, we
expected 90% to 95% rRFS at 2 years,7 and in our patients
rRFSwas 52.1%. We hypothesized that this was in part a re-
sult of enhanced detection owing to our routine use of PET/with SBRT for early-stage NSCLC based on follow-up modality (A) and
rRFS as evaluated by CT and squares (,) by PET/d-chest. The difference
(B) indicate rRFS as evaluated by CT and triangles (O) indicate only re-
thologically confirmed with biopsy. The difference between these 2 curves
te number of patients at risk at 0, 6, 12, 18, and 24 months with correspond-
, Regional recurrence-free survival; SBRT, stereotactic body radiation ther-
st, positron emission tomography combinedwith diagnostic chest computed
ery c March 2013
FIGURE 3. Representative CTand PET/d-chest images for patient 2 (see Table 2) with right hilar lymph node recurrence of NSCLC 6 months after SBRT
treatment. A and B, Pretreatment CT and PET/CT images, respectively. C and D, Six-month posttreatment CT and PET/CT images from the same PET/d-
chest examination. The yellow arrow notes the same anatomic location in the right hilum on all 4 representative images. Before treatment there was no
enlarged or hypermetabolic lymph node in this region. On the post-treatment CT scan (C), the lymph node noted by the yellow arrow measures 8 mm
in short-axis diameter. On the basis of CTevaluation criteria, this was believed to be benign/inflammatory related to prior SBRT treatment. On the posttreat-
ment PET/d-chest (D), the 8-mm lymph node believed to be benign on CTwas intensely hypermetabolic with SUVmax ¼ 5.2. Subsequent EBUS-guided
FNA biopsy confirmed recurrent NSCLC, and this patient was treated with salvage chemo/RT (66 Gy with carboplatin/paclitaxel) and is disease free 24
months after salvage therapy. CT, Computed tomography; PET, positron emission tomography; PET/d-chest, positron emission tomography combined
with diagnostic chest computed tomography;NSCLC, non–small cell lung cancer; SBRT, stereotactic body radiation therapy; SUVmax,maximum standard-
ized uptake value; EBUS, endobronchial ultrasound; FNA, fine needle aspiration; RT, radiotherapy.
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Sd-chest, rather than CT alone. Figure 3 demonstrates an ex-
ample of a nodal recurrence detected by PET/d-chest that
would have been missed by anatomic CT imaging alone.
Because of the manner in which our follow-up scans were
performed (as combined diagnostic chest CTwith contrast,
and PET) we were able to separate the studies and reinter-
pret the CT component without knowledge or bias from
the PET and report rRFS separately as determined by
each modality. To our knowledge, this type of analysis
with internal controls has not been performed previously.
It allowed us to truly distill the added value of biologic
imaging after SBRT. Most prior studies have focused on
the utility of PET for detection of local recurrence within
the target volume only.8,9,14 Inasmuch as a significant
proportion of patients demonstrate elevated FDG uptake
within the target volume for several months after SBRT,
the value of PET, especially within the first 6 months after
treatment, is controversial. Data presented here, however,
clearly indicate an important role for PET as the optimal
mode of surveillance for potentially salvageable regionalThe Journal of Thoracic and Carecurrence. Evaluation of the regional lymphatics is
particularly relevant when one considers that many
patients receiving SBRT undergo radiographic staging
only, whereas surgical resection offers the opportunity of
pathologic staging at the time of resection.
There were no detected regional recurrences when
follow-up evaluation was limited to CT alone. The addition
of PET aided in the detection of 10 regional recurrences in
the same 35 patients. Table 2 outlines details of these recur-
rences. Because of the known and clinically relevant false-
positive rate of PET/CT for mediastinal staging, we sought
pathologic confirmation of suspected recurrences whenever
possible.15 The majority (60%) of the recurrences were
confirmed pathologically. Even when one considers only
those recurrences that were pathologically confirmed,
sensitivity for regional recurrence remains significantly im-
proved with the addition of PET to diagnostic CT imaging.
It is unclear whether earlier detection of regional recur-
rences will significantly affect overall survival in this med-
ically frail patient population, where few are fit for salvagerdiovascular Surgery c Volume 145, Number 3 713
TABLE 2. Characteristics of patients with regional recurrence
Demographic Tumor/staging Treatment Recurrence Status
Pt Age Sex
ECOG
PS
AJCC
T stage
LD
(cm)
Tumor
location
Invasive
mediastinal
staging?
SBRT
(Gy [BEDGy10])
rRFS
(mo)
Biopsy-
proven (Y/N)
Salvage
treatment
Alive/
dead
Survival
(mo)
1 61 F 2 1b 2.9 Peripheral None 56 [134.4] 16.5 Y None Dead 31.7
2 64 F 1 1a 1.4 Peripheral None 56 [134.4] 6 Y CRT Alive 36.9
3 73 F 1 2b 5.3 Peripheral None 56 [134.4] 14 N* CRT Dead 34
4 53 F 2 1a 1.6 Peripheral MED/EBUS 56 [134.4] 29.2 N None Alive 32.8
5 68 M 1 1a 1.2 Peripheral None 56 [134.4] 3 Y Chemo Dead 24
6 69 F 1 1a 1.5 Peripheral None 60 [180] 15.3 Y CRT Dead 28.6
7 81 F 2 1b 2.4 Peripheral None 50 [112.5] 4.6 N None Dead 18.3
8 63 F 2 1b 3.3 Peripheral EBUS 56 [134.4] 2.9 Y None Dead 9.9
9 71 F 3 1a 2 Peripheral None 60 [180] 3.9 Y CRT Dead 26.1
10 77 F 3 2b 5.4 Peripheral None 50 [100] 3.3 N None Dead 11.3
ECOG, Eastern Cooperative Oncology group; PS, performance status; AJCC,American Joint Commission on Cancer; LD, longest diameter of the tumor on the pretreatment chest
computed tomogram; SBRT; stereotactic body radiation therapy; BEDGy10, biologically equivalent radiation therapy dose determined using the linear quadratic equation with a/
b ¼ 10; rRFS, regional recurrence free survival; CRT, chemoradiotherapy; MED, mediastinoscopy; EBUS, endobronchial ultrasound. *This patient received salvage treatment
even though pathologic confirmation of recurrence was not obtained owing to very high clinical suspicion.
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Streatment. However, as indications for SBRT are expanded
to perhaps include the high-risk yet operable patients for
whom salvage treatment may be feasible, early detection
of locoregional recurrence becomes highly relevant. Of
note, all of the regional cancer recurrences in our patients
occurred in the absence of distant metastatic cancer, further
increasing the chance for successful salvage. Five of these
patients received no salvage treatment because they were
candidates for neither extended-field thoracic reirradiation
nor systemic chemotherapy.
Various strategies have been used for the treatment of
locoregional recurrence after definitive treatment of
early-stage NSCLC. Conventionally fractionated radiation
therapy after initial resection has been shown to result in
some long-term survivors, justifying a second attempt at
definitive local therapy.16,17 Conversely, salvage surgical
resection after conventionally fractionated definitive
radiation therapy is warranted in selected cases.18 Also,
salvage surgical resection, including anatomic lobectomy
and segmentectomy, can be safely performed after SBRT
as well.19 This is confirmed by experience at our own in-
stitution. Reirradiation is also feasible in patients with lon-
ger disease-free intervals and a reasonable performance
status.20 Newer evidence suggests that definitive conven-
tionally fractionated radiation therapy (or chemoradiother-
apy) can be performed for hilar and/or mediastinal
regional recurrence after SBRT with some success.21
Four of our patients who had regional lymph node recur-
rences without local recurrence subsequently underwent
salvage treatment consisting of mediastinal/hilar radiation
therapy combined with chemotherapy in a similar fashion
to previously reported salvage treatments.21 These experi-
ences justify more sensitive surveillance of patients under-
going SBRT, especially those with favorable performance
status, with periodic PET/d-chest as salvage may be714 The Journal of Thoracic and Cardiovascular Surgpossible. A nihilistic approach to locoregional recurrence
is inadequate.
Regional recurrence is relatively uncommon in prior stud-
ies of lung SBRT. In the RTOG0236 study, only 2 patients of
55 had regional recurrence, at 33 and 36 months. PET was
not mandated. It is unclear whether these recurrences might
have been detected earlier had PET scanning been per-
formed or whether additional regional recurrences had
gone undetected before either progression to disseminated
disease or termination of follow-up. Other variables may
have contributed to the higher than expected regional recur-
rence rates in the current study. Inaccurate clinical staging
may have been a factor, especially in those patients with
early (<6 months after SBRT) recurrences. Initial radio-
graphic staging was performed with CT, PET, and brain
CT or magnetic resonance imaging. Many of the pretreat-
ment scans were performed at outside referring institutions
and could not be repeated owing to insurance issues. As
such, the scan timing, technique, and accuracy of the read-
ings were not standardized. Invasive staging with mediasti-
noscopy, EBUS, and/or endoscopic esophageal ultrasound
were aggressively yet selectively performed as a function
of tumor size, mediastinal/hilar nodal size, patient perfor-
mance status, and patient preference. The importance of
invasive staging before nonoperative treatments is underem-
phasized, because we know that EBUS discovers mediasti-
nal disease in roughly 10% of PET/CT-negative and 16%
of CT-negative patients.22 This is especially important in pa-
tients with central tumors, where 50% harbor nodal disease
regardless of T stage.23 Another possible factor could have
been unintentional underdosage of the planning target vol-
ume because of inherent inaccuracies in the Ray-Tracing
dose-calculation algorithm used for the first 18 months of
our program. In 2010 the extreme variability in actual dose
delivered (vs intended dose) with this technique wasery c March 2013
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lung tumors. Subsequently, we used the more robust Monte
Carlo algorithm.24 Longer follow-up will be necessary to
determine whether this was truly a factor in this series.
In summary, our series demonstrates that PET/d-chest
enhances the detection of regional progression of NSCLC
after SBRTover currently recommended radiographic strat-
egies. The superiority of the addition of PET to diagnostic
CT is critically important inasmuch as it pertains to ongoing
and planned prospective studies evaluating SBRT for the
treatment of patients with operable NSCLC. Since patients
enrolled in these studies are likely to be healthier and can
potentially tolerate salvage treatment with surgery or che-
moradiotherapy, early detection is paramount. Delays may
result in further cancer dissemination with no chance for
salvage and ultimately compromise survivals. Although
our data cannot be used to determine the optimal frequency
of posttreatment follow-up with PET, it is essential that it be
combined with anatomic imaging to enhance the early de-
tection of regional cancer recurrences. In conclusion, we
strongly recommend that all prospective and/or cooperative
group studies of SBRT for the treatment of patients with
borderline-operable or operable NSCLC be amended to re-
quire PET surveillance along with diagnostic CT and that
PET/d-chest follow-up should be considered in routine
lung SBRT practice.References
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